Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce the quality of life without extending life, according to a new study led by Cedars-Sinai.
Izokibep Marches on for Psoriatic Arthritis
VIENNA — Preliminary results with the investigational interleukin-17A (IL-17A) inhibitor izokibep in a phase IIb/III trial for psoriatic arthritis (PsA) built on earlier positive findings,